BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24835804)

  • 1. Trismus and diffuse polymyalgia: an unusual presentation of recurrent metastatic ovarian cancer.
    Benjamin R; Zhai J; Morgan R; Prakash N
    BMJ Case Rep; 2014 May; 2014():. PubMed ID: 24835804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncologic outcome after recurrence in patients with stage I epithelial ovarian cancer: are clear-cell and mucinous histological types a different entities?
    Kajiyama H; Mizuno M; Shibata K; Umezu T; Suzuki S; Yamamoto E; Mitsui H; Sekiya R; Niimi K; Kawai M; Nagasaka T; Kikkawa F
    Eur J Obstet Gynecol Reprod Biol; 2014 Oct; 181():305-10. PubMed ID: 25203309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early stage mucinous ovarian cancer: A review.
    Crane EK; Brown J
    Gynecol Oncol; 2018 Jun; 149(3):598-604. PubMed ID: 29429591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of laparoscopic fertility-sparing surgery in clinically early-stage epithelial ovarian cancer.
    Park JY; Heo EJ; Lee JW; Lee YY; Kim TJ; Kim BG; Bae DS
    J Gynecol Oncol; 2016 Mar; 27(2):e20. PubMed ID: 26768783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nomogram to predict recurrence in patients with early- and advanced-stage mucinous and serous borderline ovarian tumors.
    Bendifallah S; Ballester M; Uzan C; Fauvet R; Morice P; Darai E
    Am J Obstet Gynecol; 2014 Dec; 211(6):637.e1-6. PubMed ID: 24949545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary ovarian mucinous carcinoid tumor: A case report and review of literature.
    Hsu WW; Mao TL; Chen CH
    Taiwan J Obstet Gynecol; 2019 Jul; 58(4):570-573. PubMed ID: 31307754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteosarcoma as Malignant Mural Nodule in Ovarian Mucinous Neoplasms of Intestinal Type: Report of 2 Cases.
    McFarland M; Dina R; Fisher C; McCluggage WG
    Int J Gynecol Pathol; 2015 Jul; 34(4):369-73. PubMed ID: 25760909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aggressive behavior of stage I ovarian mucinous tumors lacking extensive infiltrative invasion: a report of four cases and review of the literature.
    Ludwick C; Gilks CB; Miller D; Yaziji H; Clement PB
    Int J Gynecol Pathol; 2005 Jul; 24(3):205-17. PubMed ID: 15968194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fertility sparing surgery in early stage epithelial ovarian cancer.
    Ditto A; Martinelli F; Lorusso D; Haeusler E; Carcangiu M; Raspagliesi F
    J Gynecol Oncol; 2014 Oct; 25(4):320-7. PubMed ID: 25142621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reply: To PMID 24949545.
    Bendifallah S; Darai E
    Am J Obstet Gynecol; 2015 Jan; 212(1):116-7. PubMed ID: 25218128
    [No Abstract]   [Full Text] [Related]  

  • 11. Borderline ovarian mucinous neoplasm recurring as small cell carcinoma of hypercalcemic type: evidence for an epithelial histogenesis and relationship with ovarian mucinous tumors for this enigmatic neoplasm.
    Mansor S; Nagarajan S; Sumathi VP; McCluggage WG
    Int J Gynecol Pathol; 2011 Jul; 30(4):380-5. PubMed ID: 21623206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of recurrence and role of pelvic radiotherapy in ovarian clear cell adenocarcinoma.
    Macrie BD; Strauss JB; Helenowski IB; Rademaker A; Schink JC; Lurain JR; Small W
    Int J Gynecol Cancer; 2014 Nov; 24(9):1597-602. PubMed ID: 25275661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statistical flaws in the development of a prediction model.
    Collins GS
    Am J Obstet Gynecol; 2015 Jan; 212(1):116. PubMed ID: 25218126
    [No Abstract]   [Full Text] [Related]  

  • 14. Assessing the risk of clinical and pathologic factors for relapse of borderline ovarian tumours.
    Chang C; Chen J; Chen WA; Ho SP; Liou WS; Chiang AJ
    J Obstet Gynaecol; 2017 Feb; 37(2):233-237. PubMed ID: 27922289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of serum CA-125 levels and CA-125 tissue expression positivity in the prediction of the recurrence of stage III and IV epithelial ovarian tumors (CA-125 levels and tissue CA-125 in ovarian tumors).
    Gundogdu F; Soylu F; Erkan L; Tatli O; Mavi S; Yavuzcan A
    Arch Gynecol Obstet; 2011 Jun; 283(6):1397-402. PubMed ID: 20645105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Borderline ovarian tumors: French guidelines from the CNGOF. Part 2. Surgical management, follow-up, hormone replacement therapy, fertility management and preservation.
    Bourdel N; Huchon C; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; D'argent Mathieu E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
    J Gynecol Obstet Hum Reprod; 2021 Jan; 50(1):101966. PubMed ID: 33144266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
    Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
    Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
    BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms.
    Elias KM; Labidi-Galy SI; Vitonis AF; Hornick JL; Doyle LA; Hirsch MS; Cramer DW; Drapkin R
    Gynecol Oncol; 2014 Feb; 132(2):328-33. PubMed ID: 24342438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.